This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Transcatheter aorticvalve replacement (TAVR) has become a leading treatment for aortic stenosis, but managing thromboembolic and bleeding risks post-procedure remains challenging. This review examines current evidence on antithrombotic therapy after TAVR.
The decision between a bioprosthetic and mechanical valve is one of the most consequential for patients requiring aorticvalve replacement, said Michael Bowdish, MD, lead author of the study and a cardiothoracic surgeon at Cedars-Sinai Medical Center in Los Angeles.
BackgroundFollowing transcatheter aorticvalve replacement, acute coronary obstruction is infrequent but potentially life-threatening, while delayed coronary obstruction is even more uncommon.Case summaryA 69-year-old male underwent TAVR and subsequently developed an acute obstruction in the left main coronary artery.
(MedPage Today) -- SAN ANTONIO -- The early experience of patients needing cardiac surgery after transcatheter aorticvalve replacement (TAVR) has surgeons raising the alarm about the excess risks of these challenging procedures, based on data.
Getty Images milla1cf Mon, 01/29/2024 - 14:24 January 29, 2024 — Despite national guidelines recommending surgical aorticvalve replacement (SAVR) for patients under age 65 with severe aortic stenosis , many hospitals are still opting for a nonsurgical approach in patients under 60—possibly with poorer survival rates.
Transcatheter aorticvalve replacement (TAVR) is the standard treatment for severe aortic stenosis, but post-TAVR leaflet thrombus, identified by hypoattenuated leaflet thickening (HALT), poses potential risks like cerebral thromboembolic events. had thrombus at any aorticvalve complex.
(MedPage Today) -- Transcatheter aorticvalve replacement (TAVR) yielded clinical benefit when given early in the disease process while patients still had no symptoms or other indication for aorticvalve replacement, according to the EARLY TAVR.
Small aortic annulus poses a major challenge in aorticvalve replacement due to the increased risk of prosthesispatient mismatch (PPM) and increased surgical risk. In recent years, transcatheter aorticvalve replacement (TAVR) has emerged as a popular alternative to the traditional surgical aorticvalve replacement.
ObjectivesRegistered, prospective, multicenter study of the short-term clinical outcomes of a novel transcatheter aorticvalve system (Xcor system, Saint Medical Technology, Inc.,
Background Subclinical leaflet thrombosis (SLT) is a common complication after transcatheter aorticvalve replacement (TAVR). Methods This prospective cohort study consecutively enrolled patients with severe symptomatic aortic stenosis who underwent successful TAVR. Trial registration number ChiCTR2300072300.
Valvular heart disease, including calcific or degenerative aortic stenosis (AS), is increasingly prevalent among the older adult population. Over the last few decades, treatment of severe AS has been revolutionised following the development of transcatheter aorticvalve replacement (TAVR).
Data shows, versus surgery, the Evolut transcatheter aorticvalve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years, strong valve performance and durable clinical outcomes. Evolut TAVR vs. 9.3% Evolut TAVR vs. 9.3% Grubb, M.D., 1 Herrmann H.
Aortic Stenosis (AS) is a common condition with an estimated pooled prevalence of all AS in the elderly population at around 12.4%, with that of severe AS estimated to be around 3.4%. In the past, surgical aorticvalve replacement was the primary treatment option for severe AS for decades.
The optimal management of concomitant chronic obstructive coronary artery disease (CAD) in transcatheter aorticvalve replacement (TAVR) recipients remains a debated topic. While some advocate for pre-TAVR percutaneous coronary intervention, others adopt an expectant approach. Original article: Persits I et al.
(MedPage Today) -- NEW YORK CITY -- Researchers eked out evidence of a small clinical benefit with the Sentinel cerebral embolic protection (CEP) device in transcatheter aorticvalve replacement (TAVR) -- and pointed to the patients more likely.
(MedPage Today) -- LONDON -- Some individuals already undergoing transcatheter aorticvalve replacement (TAVR, also TAVI) might as well get coronary lesions revascularized around the same time, according to the NOTION-3 randomized trial. Clinical.
Morristown Medical Center’s Gagnon Cardiovascular Institute’s structural heart program recently reported it has reached a significant milestone of performing over 5,000 transcatheter aorticvalve replacement (TAVR) procedures, the first in New Jersey and among the first to accomplish this in the United States.
We know TAVI is in the striking distance , to literally take over most aorticvalve interventions. While the numbers increase, still the debate between SAVR and TAVR is riddled with speculation, skepticism, and absolute confidence. Lastly, TAVI’s lifespan* is currently less than half of a mechanical valve.
TAVR and SAVR are procedures to replace a damaged aorticvalve that is not functioning properly. TAVR and SAVR are procedures to replace a damaged aorticvalve that is not functioning properly. Researchers randomly assigned half of the participants to undergo TAVR and the other half to SAVR.
Molham Aldeiri , have successfully performed the first series of transcarotid Transcatheter AorticValve Replacement (TAVR) procedures ever done in Southeast Houston. TAVR , whether through the groin approach or neck approach, only requires a half-inch or inch incision.
(MedPage Today) -- With protamine routinely given at the end of transcatheter aorticvalve replacement or implantation (TAVR or TAVI), patients achieved hemostasis quicker and with greater success, according to the ACE-PROTAVI trial. Successful.
(MedPage Today) -- ATLANTA -- For transcatheter aorticvalve replacement (TAVR) candidates with a small aortic annulus, the two leading platforms offered differing hemodynamic valve performances despite being similarly effective at 1 year, according.
milla1cf Fri, 06/07/2024 - 14:50 June 7, 2024 — Medtronic today announced new data from the CoreValve Evolut Clinical Program , reinforcing the positive performance of the Evolut transcatheter aorticvalve replacement (TAVR) System compared to surgical aorticvalve replacement (SAVR) and other TAVRvalves.
Objectives The clinical outcomes of transcatheter aorticvalve replacement (TAVR) in patients with aortic stenosis (AS) and concomitant active cancer remain insufficiently explored. This study aimed to assess the midterm outcomes of TAVR in patients diagnosed with AS and active cancer. vs 74.7%, p=0.50).
The DAIC team has learned of the passing of Alain Cribier, MD, FACC, heralded as the man who pioneered the first transcatheter aorticvalve replacement (TAVR) in 2002, as well as the first transcatheter mitral commissurotomy in 1995 and the first balloon aortic valvuloplasty in 1986. He passed away Feb.
milla1cf Thu, 03/28/2024 - 07:30 March 28, 2024 — Medtronic plc, a global leader in healthcare technology, announced that the United States Food and Drug Administration ( FDA ) has approved the Evolut FX+ transcatheter aorticvalve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis.
(MedPage Today) -- Alain Cribier, MD, who performed the first transcatheter aorticvalve replacement (TAVR) in 2002, died last week at age 79, the American College of Cardiology announced. Higher lipoprotein(a) went hand in hand with increased.
New data reveal that percutaneous coronary intervention (PCI) can be safely performed before, during, or after transcatheter aorticvalve replacement (TAVR) for patients with stable coronary artery disease (CAD).
IntroductionSince TAVR was approved for lower-risk aortic stenosis (AS) patients, managing post-implantation conduction disturbances has become crucial, especially with self-expanding heart valves (SEV).
Some patients with aortic stenosis may require multiple valve interventions in their lifetime, and choosing transcatheter aorticvalve replacement (TAVR) as the initial intervention may be appealing to many. If their transcatheter heart valve degenerates later in life, most will hope to undergo redo-TAVR.
Transcatheter aorticvalve replacement (TAVR) has increased in utilization since its approval for management of aortic stenosis patients across all risk strata. We report a rare case of aorticvalve leaflet av.
Getty Images milla1cf Wed, 05/15/2024 - 19:10 May 15, 2024 — A new study demonstrated parity between a minimally invasive procedure to replace the aorticvalve in the heart— transcatheter aorticvalve replacement (TAVR)—and surgical aorticvalve replacement (SAVR).
This cohort study examines whether there is an association between osteosarcopenia and adverse outcomes, such as increased risk of mortality, in older adults following transcatheter aorticvalve replacement (TAVR).
Procedure trends certainly suggest that we’ve entered the TAVR era, but a pair of new studies show that surgical aorticvalve replacement (SAVR) is a far better option for many younger and healthier patients who are increasingly seen as TAVR candidates.
What is the 5-year incidence of valve reintervention after self-expanding CoreValve/Evolut transcatheter aorticvalve replacement (TAVR) versus surgical aorticvalve replacement (SAVR)?
How do mortality and morbidity compare after valve-in-valve (ViV) transcatheter aorticvalve replacement (TAVR) versus redo surgical aorticvalve replacement (SAVR) for intervention for a failed bioprosthetic SAVR?
Aortic stenosis is a narrowing of the aorticvalve which prevents the aortic leaflets from opening and closing properly. Two common approaches for treating aortic stenosis include surgical aorticvalve replacement (SAVR) and transcatheter aorticvalve replacement (TAVR).
(MedPage Today) -- Operators reported the initial success of a novel transcatheter technique for treating complex paravalvular leaks (PVLs) after transcatheter aorticvalve replacement (TAVR) or transcatheter mitral valve replacement (TMVR) in.
IntroductionClinical evidence highlighting the efficacy and safety of transcatheter aorticvalve replacement (TAVR) and the 2019 Food and Drug Administration (FDA) approval for TAVR in low-risk (younger) patients has created a demand for durable and long-lasting bioprosthetic heart valve (BHV) leaflet materials.
Blog Global Differences in Managing Patients with AorticValve Disease KCummings Thu, 10/24/2024 - 09:42 Adult Cardiac All Members It is time to reconsider the management of Aorticvalve Disease (AVD) across the world. Patients receive mechanical valves.
SAVR after TAVR Surgical aorticvalve replacement after prior TAVR is the fastest-growing cardiac surgery procedure in the U.S. The majority require explant of the TAVR device and SAVR, which significantly increases the risk of operative mortality and stroke. and 3.8%, respectively.
The occurrence of TTP subsequent to an emergent aorticvalve replacement after a TAVR procedure is exceedingly uncommon with only a f. Thrombotic thrombocytopenic purpura (TTP) is a rare hematological disorder.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content